ReviewMolecular diagnosis & therapy2008
NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS.
Review in Molecular diagnosis & therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 57 citations in OpenAlex.
- Recent advances in nanotherapeutics for HIV-associated neurocognitive disorders and substance use disorders.Nanomedicine (London, England) · 2025Review
- Intestinal barrier compromise, viral persistence, and immune dysregulation converge on neurological sequelae in Long COVID.Frontiers in aging neuroscience · 2025Review
- Review
- Review
- Sleep disturbance and associated factors among Nigerian adults living with HIV in the dolutegravir era.Frontiers in sleep · 2022Article
- Mental illness and HIV amongst female inmates in Durban, South Africa.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2022Article
- Detection of subtype-specific breast cancer surface protein biomarkers via a novel transcriptomics approach.Bioscience reports · 2021Article
- An HIV Narrative of Female Inmates With a Lifetime History of Mental Illness in Durban, South Africa.Frontiers in psychiatry · 2021Article
- Nose to brain delivery of antiretroviral drugs in the treatment of neuroAIDS.Molecular biomedicine · 2020Review
- Common gene-network signature of different neurological disorders and their potential implications to neuroAIDS.PloS one · 2017Article
- Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.Bioorganic & medicinal chemistry · 2016Article
- Tryptophan Metabolism and Its Relationship with Depression and Cognitive Impairment Among HIV-infected Individuals.International journal of tryptophan research : IJTR · 2016Article
- Structural gray matter change early in male patients with HIV.International journal of clinical and experimental medicine · 2014Article
- Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies.Current topics in medicinal chemistry · 2014Review
- Human immunodeficiency virus-1 protein Tat induces excitotoxic loss of presynaptic terminals in hippocampal cultures.Molecular and cellular neurosciences · 2013Article
- New tools for the investigations of Neuro-AIDS at a molecular level: The potential role of data-mining.Bioinformation · 2013Article
- Genetic variation and HIV-associated neurologic disease.Advances in virus research · 2013Review
- Article
- Subtype selective NMDA receptor antagonists induce recovery of synapses lost following exposure to HIV-1 Tat.British journal of pharmacology · 2012Article
- An initial screening for HIV-associated neurocognitive disorders of HIV-1 infected patients in China.Journal of neurovirology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
The neurological complications of AIDS (NeuroAIDS) include neurocognitive impairment and HIV-associated dementia (HAD; also known as AIDS dementia and HIV encephalopathy). HAD is the most significant and devastating central nervous system (CNS) complications associated with HIV infection. Despite recent advances in our knowledge of the clinical features, pathogenesis, and neurobiological aspects of HAD, it remains a formidable scientific and therapeutic challenge. An understanding of the mechanisms of HIV neuroinvasion, CNS proliferation, and HAD pathogenesis provide a basis for the interpretation of the diagnostic features of HAD and its milder form, HIV-associated minor cognitive/motor disorder (MCMD). Current diagnostic strategies are associated with significant limitations, but it is hoped that the use of biomarkers may assist researchers and clinicians in predicting the onset of the disease process and in evaluating the effects of new therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.